Insilico Medicine
PrivateLast Round
IPO
Dec 30, 2025
Est. Valuation
$1.72B
Total Funding Raised
$854.01M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Insilico Medicine is a biotechnology company that develops an advanced AI platform and innovative drugs aimed at providing transformative solutions for cancer, fibrosis, immune disorders, central nervous system diseases, and age-related conditions.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Insilico Medicine Comparables
Compare Insilico Medicine with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XtalPi | 89% | |
| BenevolentAI | 84% | |
| BioMap | 83% |
For institutional investors. Book with your work email.
Insilico Medicine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Dec 30, 2025 | ||||
| Series E | Jun 16, 2025 | ||||
| Series E | Mar 13, 2025 | ||||
| Series E | Jan 7, 2025 | ||||
| Debt | Nov 5, 2024 | ||||
Series D Extension | Aug 10, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Insilico Medicine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series C, Series D Extension |
| AIBasis Fund | Series C |
| Credit Suisse Asset Management | ipo |
| Temasek | ipo, Series B |
| Lake Bleu Capital | Series C |
| Winter Capital | Series C |
| 上海浦东创业投资有限公司 | Series E |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Launched Longevity Grok platform in collaboration with David Sinclair.
- Nov 6, 2026
Released Longevity Grok, a Personal Longevity Superintelligence.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 6, 2026
Insilico Medicine, Inc. launches the longevitygrok.si website and announces the open-source release of Longevity Grok, a multi-agent AI system for unifying personal health records, tracking biological analysis, generating personalized lifestyle interventions, and supporting geroscience research, in Massachusetts on Nov. 6th '26.
- launchesNov 6, 2026
Insilico Medicine, Inc. announces the open-source release of Longevity Grok, the Personal Longevity Superintelligence, and launches its website in Massachusetts on Nov. 6th '26; the multi-agent AI system unifies personal health records, tracks biological data, and generates personalized health interventions.
- attends_eventNov 2, 2026
Insilico Medicine, Inc. is invited to attend the 2026 Future Healthcare Investment Market (FHIM) annual conference in China on Nov 4th '26, where Dr. Feng Ren is set to deliver a keynote on AI-driven small-molecule R&D.
- attends_eventNov 1, 2026
Insilico Medicine, Inc.'s Dr. Jue Wang is invited to attend the China Healthcare Summit in China from Nov 2nd–4th '26 and is scheduled to deliver a keynote on Nov 3rd '26.
- launchesOct 21, 2026
Insilico Medicine, Inc. launches inClinico Agent, an agentic AI workspace that automates clinical trial intelligence and predicts trial outcomes, on Oct 21st '26.
For institutional investors. Book with your work email.
Insilico Medicine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Insilico Medicine's valuation, stock price, and market status.
Is Insilico Medicine a public or private company?
Insilico Medicine is a private company.
What is the current stock price of Insilico Medicine?
Insilico Medicine is a private company, so its shares have no public market price. Caplight tracks Insilico Medicine's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Insilico Medicine worth (valuation)?
Insilico Medicine's valuation is estimated at $1.7B based on funding round data.
Can I buy Insilico Medicine stock?
Insilico Medicine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Insilico Medicine's last funding round?
Insilico Medicine's most recent funding round was ipo on December 30, 2025.
Who are the main investors in Insilico Medicine?
Key investors in Insilico Medicine include 上海浦东创业投资有限公司, China International Capital Corporation, Morgan Stanley, Aramco Ventures, Value Partners Group.
Will Insilico Medicine IPO soon?
No public IPO plans have been announced for Insilico Medicine.
How can I track Insilico Medicine secondary market activity?
Caplight tracks bids, offers, and trades in Insilico Medicine's shares on secondary markets.